Professor Dale Vimalachandran

Qualifications

MB ChB, MD, FRCS (Eng)

GMC number: 4409483

Practising since: 1997

Specialties

General Surgery, Colorectal Surgery

Consultation times

  • Wednesdays
  • Overview
Book online today Enquire now

Or call us on

01244 680 444

About

Professor Dale Vimalachandran has been a Consultant Colorectal Surgeon at the Countess of Chester since 2010. He is a Reader/Associate Professor in the Department of Molecular and Clinical Cancer Medicine at the University of Liverpool, where he runs a successful colorectal cancer research group.

He qualified in 1997 and undertook specialist fellowships at the Cleveland Clinic in the USA, trauma units in South Africa and pelvic floor surgery in Manchester.

He offers expertise in all aspects of colorectal surgery and general surgery, with a specialist interest in colorectal cancer, IBS, diverticular disease and colonoscopy. He is the lead investigator for the worldwide DAMASCUS study, looking at the management of diverticular disease.

To date, he has conducted numerous national and international clinical trials in general and colorectal surgery.

He has supervised PhD students at the University of Liverpool and currently runs the Northwest Colorectal Clinical Higher Research Degree Programme and the Cancer Sampling Programme. His current research spans all aspects of colorectal cancer from early detection, through to personalised cancer therapy and palliative care.

He has published over 125 scientific papers and book chapters, and is currently the national research speciality lead for colorectal surgery at the Royal College of Surgeons of England.

He was the NIHR national specialty lead for cancer surgery and is the deputy chair of the scientific committee for Bowel Research UK, the largest bowel surgery charity in the UK.

He was the clinical lead for general surgery at the Countess of Chester and the associate medical director for planned care. He is also the deputy chair of the clinical ethics committee for the Countess of Chester and is a member of the University of Liverpool clinical ethics committee.

He can offer surgical intervention for a wide range of general surgical and colorectal conditions. He commonly performs:

  • Colonoscopy
  • Flexible sigmoidoscopy
  • Treatment of haemorrhoids, fissure, fistula and abscesses
  • Inguinal and abdominal wall hernia repair

He can provide advice on a wide range of conditions, but in particular diverticular disease, IBS and bowel cancer.

Other interests

Surgical Training.

Treatments and tests offered by Professor Dale Vimalachandran at Nuffield Health

  • Colonoscopy
  • Colorectal surgery

Locations Professor Dale Vimalachandran works with

Related experience

Research

·       Fowler H, Clifford RE, Bowden D, Sutton PA, Govindarajah N, Fok M, Glenn M, Wall M, Rubbi C, Buczacki SJA, Mandal A, Francies H, Hughes J, Parsons JL, Vimalachandran D. Myoferlin: A Potential Marker of Response to Radiation Therapy and Survival in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2024 Jun 10:S0360-3016(24)00696-5. doi: 10.1016/j.ijrobp.2024.05.030. Epub ahead of print. PMID: 38866213.

·       Fok M, Hill R, Fowler H, Clifford R, Kler A, Uzzi-Daniel J, Rocha S, Grundy G, Parsons J, Vimalachandran D. Enhancing radiotherapy outcomes in rectal cancer: A systematic review of targeting hypoxia-induced radioresistance. Clin Transl Radiat Oncol. 2023 Oct 28;44:100695. doi: 10.1016/j.ctro.2023.100695. PMID: 37961749; PMCID: PMC10637894.

·       Jones RP, Lee LYW, Corrie PG, Danson S, Vimalachandran D. Individualized cancer vaccines versus surveillance after adjuvant chemotherapy for surgically resected high-risk stage 2 and stage 3 colorectal cancer: protocol for a randomized trial. Br J Surg. 2023 Nov 9;110(12):1883-1884. doi: 10.1093/bjs/znad332. PMID: 37856683.

·       Jones RP, Mielgo A, Schmid M, Bury D, Andrews T, Burdak-Rothkamm S, Shackcloth M, J S Cross T, Fenwick S, Malik HZ, Diaz-Nieto R, Ottensmeier C, Palmer DH, Vimalachandran D. PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research. Br J Surg. 2023 Aug 11;110(9):1108-1111. doi: 10.1093/bjs/znad097. PMID: 37075549.

·       Vimalachandran D. Neoadjuvant chemotherapy for locally advanced colonic cancer is not ready to be the standard of care. Br J Surg. 2023 Nov 9;110(12):1677-1678. doi: 10.1093/bjs/znad184. PMID: 37740527.

·       Vimalachandran D, Jones RP, Dickson E, Seehra J, Acheson A, Griffiths EA, Kamarajah S, Leung E, Torrance A, Ottensmeier C, Beggs AD, Whiteside E, Sanna H, Bury D, Youd E, Leopold G, Pugh M, Sundar S, Taylor GS. SARS-CoV-2 in the abdomen or pelvis: SAFE SURGERY study. Br J Surg. 2022 Sep 28:znac297. doi: 10.1093/bjs/znac297. 

·       Bellomo G, Rainer C, Quaranta V, Astuti Y, Raymant M, Boyd E, Stafferton R, Campbell F, Ghaneh P, Halloran CM, Hammond DE, Morton JP, Palmer D, Vimalachandran D, Jones R, Mielgo A, Schmid MC. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Gut. 2022 Jan 12:

·       Lee RW, Danson S, Elliot M, Park EI, Pinkney TD, Shaw CE, Vimalachandran D, Maughan T, Seymour M, Corrie P, Wadsley J. Importance of clinical research for the UK's 10-year cancer plan. Lancet Oncol. 2022 Jun 9:S1470-2045(22)00292-3. doi: 10.1016/S1470-2045(22)00292-3. *

·       Clifford RE, Harji D, Poynter L, Jackson R, Adams R, Fearnhead NS, Vimalachandran D; ReCaP Steering Committee and Collaborators. Rectal cancer management during the COVID-19 pandemic (ReCaP): multicentre prospective observational study. Br J Surg. 2021 Nov 11;108(11):1270-1273.

·       Fok M, Toh S, Easow J, Fowler H, Clifford R, Parsons J, Vimalachandran D. Proton beam therapy in rectal cancer: A systematic review and meta-analysis. Surg Oncol. 2021 Sep;38:101638. doi: 10.1016/j.suronc.2021.101638. Epub 2021 Jul 27. PMID: 34340196.

·       R Clifford, N Govindarajah, D Bowden, P Sutton, U McDermott, Zdzislaw S, B Ogretmen, J.L. Parsons, D Vimalachandran. Targeting acid ceramidase to improve the radiosensitivity of rectal cancer. Cells 2020 Dec 15;9(12):2693

·       H Fowler, R Clifford, P Sutton, A Watson, N Fearnhead, S Bach, B Moran, A Rose, R Jackson, D Vimalachandran on behalf of the HiP collaborators. Hartmann’s procedure versus Intersphincteric APE (HiP Study): A Multicentre Prospective Cohort Study. Colorectal Dis 2020 Dec;22(12):2114-2122.

·       Cleberson J S Queiroz, Fei Song, Karen R Reed, Alan R Clarke, Al Khafaji N, Vimalachandran D, Fabio Miyajima, David Mark Pritchard, John R Jenkins.  NAP1L1: a novel human colorectal cancer biomarker derived from animal models of Apc inactivation. Front Oncol. 2020 Aug 11;10:1565.

·       Sutton P1,2, Vimalachandran D2, Poston G1, Fenwick S1, Malik H1  J. Oncosurgical Management of Liver Limited Stage IV Colorectal Cancer: Preliminary Data and Protocol for a Randomized Controlled Trial. MIR Res Protoc. 2018 May 9;7(5)

Memberships

  • Association of Surgeons
  • Association of Coloproctology of Great Britain and Ireland
  • Royal College of Surgeons of England

Other posts held

  • Consultant General & Colorectal Surgeon, Countess of Chester Hospital

Insurers Professor Dale Vimalachandran works with

Professor Dale Vimalachandran works with the following private medical insurance providers:

  • Aviva Health
  • AXA Health
  • Bupa
  • Cigna
  • CS Healthcare
  • Exeter Family Friendly
  • Simplyhealth
  • WPA

Declaration

Professor Dale Vimalachandran does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.

Professor Dale Vimalachandran does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.

Professor Dale Vimalachandran does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.